## Deep Dive into the Next Breakthrough Immuno-Oncology Target

**April 17th, 2019 | Boston, MA**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00</td>
<td>Registration, Breakfast &amp; Networking</td>
</tr>
<tr>
<td>9:00</td>
<td>Chair’s Opening Remarks &amp; Setting the Scene</td>
</tr>
<tr>
<td>9:00</td>
<td>Keynote Presentation: CD47/SIRPα: Why this Pathway, Why Now and the Importance of Collaboration?</td>
</tr>
<tr>
<td>9:10</td>
<td><strong>Kipp Weiskopf</strong>, Physician/Scientist, Hematology/Oncology Fellow, Dana-Farber Cancer Institute</td>
</tr>
</tbody>
</table>

Research into immunotherapeutics is at the forefront of cancer science and the hunt for novel targets and innovative therapies is ongoing. In a field that has a number of avenues to explore, the CD47/SIRPα checkpoint is increasingly proving to be an effective potential target for immunotherapeutics.

- A look at the history of developing CD47/SIRPα as a therapeutic target
- Discuss how the CD47/SIRPα pathway is a unique immune-oncology target differentiated from other IO approaches
- Highlight recent results of CD47/SIRPα targeting in the clinic

**Mark Chao**, Co-Founder & Vice President of Clinical Development, Forty Seven Inc.
9:35 **Presentation:** Capturing Drug-Induced Modulation of the Tumor Microenvironment Using A Personalized Ex Vivo Histoculture Approach

- Mitra Biotech has developed and clinically validated our fully human ex vivo platform technology (CANscript™).
- CANscript™ uses patient material (tumor, autologous ligands and PBMCs) to explore the mechanism of action and biomarker identification.
- CANscript™ predicts efficacy for clinically-directed compounds in a modality-agnostic way using phenotypic effects.

**Stefan Jellbauer**, Technical Liaison, **Mitra Biotech**

10:00 **Panel Discussion and Open Q&A:** Understanding the Fundamental Biology of the CD47/SIRPα Checkpoint

CD47/SIRPα immunotherapeutics is an emerging field and the excitement of developing potential life-saving therapeutics is huge. The modern era of cancer research began at the turn of the 19th century. However, the understanding of foundational cancer biology has limited progression. Use this panel to pose questions to the industries academic leaders and pioneering Biotech companies.

- What is our current understanding of the structure and mechanisms of the CD47/SIRPα interaction?
- How does the CD47/SIRPα checkpoint work to inhibit the natural immune response?
- What are the polymorphisms that have to be taken into account when designing therapeutics for them to have efficacy?
- A look into the importance of inducing phagocytes from the periphery. What is the mechanisms responsible and how can we achieve this?
- Are we eagerly moving forward without fully understanding the fundamental biology?
- What is our understanding of the tumour microenvironment and what effect does it have on macrophages?
- Can toxicity be expected based on expression patterns of CD47/SIRPα?

Moderated by: **Kipp Weiskopf**, Physician/Scientist, Hematology/Oncology Fellow, Dana-Farber Cancer Institute  
**Walter Ferlin**, Head of Exploratory Science and Translational Medicine, Novimmune  
**Andre Veillette**, Professor, Department of Medicine, University of Montreal  
**Sergio Trombetta**, Senior Principal Scientist, Cancer Immunology & Immune Modulation, Boehringer Ingelheim  
**Timo Van Den Berg**, Professor of Immunotherapy, Head Department of Blood Cell Research, Sanquin Research, Amsterdam University Medical Center

10:40 **Morning Refreshments & Networking**
### Targeting CD47 vs SIRPα

**Deep Dives into the Different Approaches**

<table>
<thead>
<tr>
<th>Time</th>
<th>Case Study</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>11:15</strong></td>
<td><strong>Case Study 1</strong> - Looking at Trillium Therapeutics Approach to Targeting CD47</td>
<td></td>
</tr>
</tbody>
</table>
- Rationale for developing fusion proteins targeting CD47  
- Unique properties of TTI-621: IgG1 isotype, lack of RBC binding  
- Emerging clinical and translational data  
- Next steps: Monotherapy and combination strategies  
  
  **Bob Uger**, Chief Scientific Officer, **Trillium Therapeutics** |
| **11:40** | **Case Study 2** - An Insight into ALX Oncology’s Approach to Targeting CD47-SIRPα pathway |  
- A look at ALX’s pipeline and their approach in targeting CD47 while avoiding hematological toxicity  
- A discussion as to their focus on combination therapy  
- Looking at some of the preclinical and clinical data  
  
  **Hong Wan**, Chief Scientific Officer, **ALX Oncology** |
| **12:05** | **Case Study 3** - A Look into OSE Immunotherapeutics Approach to Targeting SIRPα |  
- An understanding why OSE are targeting SIRPα over CD47  
- A look into OSE’s ideas on monotherapy and combination therapies  
- Looking at some of the preclinical and translational data  
  
  **Nicolas Poirier**, Chief Scientific Officer, **OSE Immunotherapeutics** |
**12:30: Panel discussion and Open Q&A: Targeting CD47 vs SIRPα: Is there an Optimal Approach for Targeting the CD47/SIRPα Axis?**

The CD47/SIRPα therapeutic field is a novel and emerging focus for cancer therapies. Both CD47 and SIRPα have demonstrated great results in various trials, yet the majority of pipeline therapeutics target CD47. This panel will analyze the reasons behind targeting each of the proteins in question.

- Why is there such a majority split between the two critical targets?
- What are the benefits of targeting CD47 that are making it such a hot area of research?
- What are the benefits of targeting SIRPα and should there be an increased number of trials targeting the protein?
- Which pathway is more viable as a target?
- What are the risks and detrimental off target effects caused by targeting CD47 and do we fully understand the biology we are impacting?

Moderated by **Tim Zheng**, Executive Director, Immune Modulation, **Boehringer Ingelheim**

**Mark Chao**, Co-Founder and Vice President of Clinical Development, **Forty Seven Inc**

**Bob Uger**, Chief Scientific Officer, **Trillium Therapeutics**

**Hong Wan**, Chief Scientific Officer, **ALX Oncology**

**Nicolas Poirier**, Chief Scientific Officer, **OSE Immunotherapeutics**

---

**1:10**

**Lunch & Networking**

---

**2:10 Presentation: Using a bispecific antibody approach to target CD47 blockade on tumor cells**

- Overcoming the challenge of ubiquitous CD47 expression
- Achieving favorable antibody pharmacokinetics and avoiding hemotoxicity
- Enhancing macrophage driven tumoricidal activity by remodeling the cancer cell microenvironment

**Walter Ferlin**, Head of Exploratory Science and Translational Medicine, **Novimmune**

---

**2:35 Presentation: Development of a Ready-to-use, MOA Reflective, Cell-Based Signalling Assay for Characterization and Potency Determination of anti-CD47 Therapeutics**

- With several therapeutics targeting the SIRPa/CD47 axis moving into clinical trials, a robust, MOA-reflective cell-based assay to support the development of the drug candidates has becomes increasingly important
- We will describe the development and qualification of an MOA-reflective, cell-based assay that quantifies an early step in the activation cascade of SIRP α signaling
This robust assay, developed as both continuous culture and cryopreserved, assay-ready formats, allows fast and easy phase-appropriate implementation for the use in lot release and stability testing, as well as for detecting NAbs in patient samples.

Jane Lamerdin, Director of Research and Development, Eurofins DiscoverX

### A Preclinical and Translational Focus

<table>
<thead>
<tr>
<th>Time</th>
<th>Presentation: The Importance of Inducing an Adaptive Immune Response</th>
</tr>
</thead>
<tbody>
<tr>
<td>3:00</td>
<td>A look into the importance of mounting an adaptive immune response in generating immunity to the disease</td>
</tr>
<tr>
<td></td>
<td>Have we seen any successes so far in generating an adaptive immune response in preclinical and clinical trials?</td>
</tr>
<tr>
<td></td>
<td>Discussion analysing how best to promote an adaptive immune response in patients</td>
</tr>
<tr>
<td></td>
<td>Looking at the use of syngeneic mouse models in immuno-oncology preclinical trials</td>
</tr>
</tbody>
</table>

Stephanie Dougan, Assistant Professor, Dana-Farber Cancer Institute, Harvard Medical School

<table>
<thead>
<tr>
<th>Time</th>
<th>Presentation: An Insight into TG Therapeutics and their Work Leading up to Clinical Trials</th>
</tr>
</thead>
<tbody>
<tr>
<td>3:25</td>
<td>A look at TG-1801 and the mechanism of action of the therapeutic</td>
</tr>
<tr>
<td></td>
<td>A discussion focusing on TG Therapeutics entry into clinical trials</td>
</tr>
<tr>
<td></td>
<td>Looking ahead at the potential combination partners for TG-1801</td>
</tr>
</tbody>
</table>

Emmanuel Normant, Vice President, Preclinical Sciences, TG Therapeutics

The Next Generation of CD47/SIRPα Approaches

<table>
<thead>
<tr>
<th>Time</th>
<th>Presentation: Looking at the Next Generation Approaches of KAHR Medical</th>
</tr>
</thead>
<tbody>
<tr>
<td>3:50</td>
<td>A look at KAHR Medicals approach at targeting CD47 through via their bispecific fusion protein</td>
</tr>
<tr>
<td></td>
<td>Discussion focusing on the MOA of KAHR Medicals bispecific fusion protein</td>
</tr>
<tr>
<td></td>
<td>Looking at the activity of the 41BBL fusion protein and its function in activating both an innate and adaptive immune response</td>
</tr>
</tbody>
</table>
4:15  Afternoon Refreshments & Networking

4:55  Presentation: Development and Characterization of SL-172154 (SIRPα-Fc-CD40L)

- Rationale for combining CD47/SIRPα and CD40/CD40L targeting in a single therapeutic
- Overview of pre-clinical development and characterization of SL-172154
- Comparative evaluation of SL-172154 to SIRPα-Fc and anti-CD47 mAbs

Taylor Schreiber, Chief Scientific Officer, Shattuck Labs

5:20  Panel Discussion and Open Q&A: The Ins and Outs of Monotherapy and Combination Therapy Approaches with CD47/SIRPα

The current pipeline for CD47/SIRPα is packed full of varying and diverse therapeutics which have shown promising results as both mono-therapeutics and in combination therapies. This panel will discuss the findings and challenges faced during trials in both mono and combination therapies.

- What is the current successes for both mono and combination therapies?
- Are combination trials the way forward or are we seeing promising results in monotherapy trials?
- What are the potential effective combination partners?
- How well does CD47/SIRPα therapeutics pair with PD-1/PD-L1 therapies and could we see them being used together in combination therapies?
- A look into the progress in combination therapies with ADCP competent antibodies.

Moderated by Bob Uger, Chief Scientific Officer, Trillium Therapeutics

Kipp Weiskopf, Physician/Scientist, Hematology/Oncology fellow, Dana-Farber Cancer Institute

Sophia Randolph, Chief Medical Officer, ALX Oncology

Joern-Peter Halle, Senior Vice President, Head of TIP IO and Head of External Innovation, Merck KGaA

6:00  Chair’s Closing Remarks

- What have been the key learnings from today?
- Summary message of how best to implement these learnings moving forward

Kipp Weiskopf, Physician/Scientist, Hematology/Oncology fellow, Dana-Farber Cancer Institute
6:10  Close of CD47/SIRPα Summit 2019

In partnership with

MITRA BIOTECH

eurofins | DiscoverX

Produced by Grey Green Media Ltd.